Stockreport

BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the...

BeyondSpring, Inc. - Ordinary Shares  (BYSI) 
Last beyondspring, inc. - ordinary shares earnings: 4/30 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.beyondspringpharma.com
PDF Consistent OS benefit in an Asian subset with a strong HR of 0.69 for non-squamous patients, and meaningful safety advantage position Plinabulin as a late-stage candidat [Read more]